C2, characterized as a cold tumour with reduced immune cells and antigen presentation (Figure 7G), exhibits high expression of immunoinhibitor CD160 (Figure 7K), suggesting targeting CD160 provides a novel immunotherapy strategy for patients of C2. The gene discussed is CD160; the disease is neoplasm.